

María Pilar Aguar Fernández
Chair of the Global Health EDCTP3 JU Governing Board
Cc: Michael Makanga, Global Health EDCTP3 JU
Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Vienna, 21 May 2026

EDCTP Project 101249075 — EAVI: Letter of endorsement

Dear Ms Aguar Fernández, dear Mr Makanga,

On behalf of **Valneva Austria GmbH**, a limited liability company registered in Austria under company No. FN 389960 x / HG Wien, with its registered office at Campus Vienna Biocenter 3, 1030 Vienna, Austria ("**Valneva**"), and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, we hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU) under the call topic ***EAVI – European-African Vaccine Initiative: Accelerating Preventive Measures Against Chikungunya Virus in Sub-Saharan Africa.***

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary vaccines. Among them is IXCHIQ®, a single-shot vaccine against chikungunya, the disease caused by the chikungunya virus (CHIKV). This mosquito-borne viral disease is spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years¹. It was first identified in Tanzania in 1952. In 2004, the disease began to spread quickly, causing large-

¹ Morrison TE, 2014, Reemergence of Chikungunya Virus, J. Virol. 88: 11644–11647

scale outbreaks around the world. Since the reemergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas². The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem³.

We are honoured to have joined the EAVI consortium and jointly advance preventative measures to protect people in Sub-Saharan Africa from chikungunya. To support this important initiative, we will provide our long-standing expertise from the development, registration and launch of our chikungunya vaccine to devise and interpret a clinical study. We will also contribute up to 500 doses of IXCHIQ® from our commercial stock to be labelled as Investigational Medicinal Product and used for the trial.

We estimate the total value of Valneva's contribution to be

Personnel costs.....77,302.00 EUR

Vaccine (at commercial costs).....60,000.00 EUR

In total.....137,302.00 EUR

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes, and particularly the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorized by Global Health EDCTP3 JU. Internal dissemination of information within our organization will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.

² Bluedot Inc; <https://bluedot.global/vaccines-on-the-table-as-chikungunya-outbreak-intensifies-in-india/> retrieved on 07 May 2026

³ WHO (2023); <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448> retrieved on 07 May 2026

5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.
6. If our letter is accepted, and without prejudice to point 2, we authorize Global Health EDCTP3 JU to communicate about our contribution and to display our logo in its public communication materials for the purpose of acknowledging our role as a contributing partner.
7. If we are ineligible as a contributing partner but our contribution can be considered through the EDCTP Association, we authorize Global Health EDCTP3 JU to share this letter and our contact details with the EDCTP Association as proof of our declared co-investment.

Yours faithfully,

ValidSigned by Juan Carlos Jaramillo
on 22-05-2026

Dr. Juan Carlos Jaramillo
Managing Director
Valneva Austria GmbH

ValidSigned by Olivier Jankowitsch, ppa.
on 22-05-2026

Olivier Jankowitsch, ppa.
Prokurist
Valneva Austria GmbH